Skip to Content
Stock Analyst Update

UnitedHealth: Solid Quarter, Maintaining 2020 Outlook

Results and outlook for the wide-moat firm bode well for the discounted managed-care industry, and shares appear moderately undervalued.


Narrow-moat UnitedHealth Group (UNH) reported solid first-quarter operating results, and despite challenges presented by the COVID-19 crisis, particularly surrounding its own care provider operations, the company maintained its outlook for 2020. In general, UnitedHealth's results and outlook bode well for the discounted managed-care industry, and UnitedHealth shares appear moderately undervalued.

For the quarter, UnitedHealth beat Capital IQ consensus on both the top and bottom lines, and management noted that the COVID-19 crisis did not have a material impact on those results, given how late in the quarter that situation developed in the United States. Perhaps even more importantly, management also reiterated its guidance for 2020. The company continues to expect adjusted earnings per share of $16.25-$16.55 for the year, and our EPS projection remains within that range. In general, there appear to be several offsetting factors that could buoy UnitedHealth's near-term results. Also, management noted that risk-based (rather than fee-for-service) arrangements account for about two thirds of its service provider revenue, meaning about two thirds of those operations benefit from reduced care costs.

In addition to these financial disclosures, UnitedHealth also described a number of COVID-19 responses that suggest the immediate risks surrounding the health crisis are probably manageable for the organization and the industry as a whole. Investors have appeared concerned about medical costs that could rise and push down profits in a severe COVID-19 scenario. However, we suspect the inflated COVID-19 patient costs could be offset by reduced volume in other services, like routine care and elective procedures. For example, UnitedHealth's decision to assume all member costs associated with COVID-19 along with its plan to provide $2 billion of advanced payments to care providers, among other actions, suggest that overall medical costs will likely be well under control in 2020.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Julie Utterback does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.